Latest data from the HICC, EAS-led HoFH Registry

Among the abstracts presented at EAS Helsinki 2021 was important news from the EAS-led Homozygous familial hypercholesterolaemia International Clinical Collaboration (HICC) registry, the largest global database of homozygous familial hypercholesterolaemia (HoFH) patients (1). HoFH is the most severe form of FH, thought to affect about one in 300,000 to one in a million people, and […]
Share this:

Continue reading


Targeting ANGPTL3: CME Session Highlights

ANGPTL3 (angiopoietin-related protein 3) was the focus of another CME session covering basic biology, genetics and clinical trials. ANGPTL3 is an endogenous inhibitor of lipoprotein lipase, the main enzyme involved in hydrolysis of triglyceride-rich lipoproteins, as well as endothelial lipase (1). Consequently, it is a pivotal modulator of plasma triglycerides, as well as levels of […]
Share this:

Continue reading


Implementation is the challenge: CME Session Highlights

Sunday highlighted a series of CME sessions covering topical questions in lipid lowering therapy. The session ‘Novel pathways for intensive lipid lowering’ discussed how to address the two key issues in managing lipids in current practice: 1) insufficient lowering of low-density lipoprotein cholesterol (LDL‑C), a major causal risk factor for atherosclerotic cardiovascular disease, and 2) […]
Share this:

Continue reading